This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Palii, S. S.
Right arrow Articles by Robertson, K. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palii, S. S.
Right arrow Articles by Robertson, K. D.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, January 2008, p. 752-771, Vol. 28, No. 2
0270-7306/08/$08.00+0     doi:10.1128/MCB.01799-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

DNA Methylation Inhibitor 5-Aza-2'-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3B{triangledown}

Stela S. Palii, Beth O. Van Emburgh, Umesh T. Sankpal, Kevin D. Brown, and Keith D. Robertson*

Department of Biochemistry and Molecular Biology and University of Florida Shands Cancer Center Program in Cancer Genetics, Epigenetics and Tumor Virology, University of Florida, Box 100245, Gainesville, Florida 32610

Received 2 October 2007/ Accepted 25 October 2007

Genome-wide DNA methylation patterns are frequently deregulated in cancer. There is considerable interest in targeting the methylation machinery in tumor cells using nucleoside analogs of cytosine, such as 5-aza-2'-deoxycytidine (5-azadC). 5-azadC exerts its antitumor effects by reactivation of aberrantly hypermethylated growth regulatory genes and cytoxicity resulting from DNA damage. We sought to better characterize the DNA damage response of tumor cells to 5-azadC and the role of DNA methyltransferases 1 and 3B (DNMT1 and DNMT3B, respectively) in modulating this process. We demonstrate that 5-azadC treatment results in growth inhibition and G2 arrest—hallmarks of a DNA damage response. 5-azadC treatment led to formation of DNA double-strand breaks, as monitored by formation of {gamma}-H2AX foci and comet assay, in an ATM (ataxia-telangiectasia mutated)-dependent manner, and this damage was repaired following drug removal. Further analysis revealed activation of key strand break repair proteins including ATM, ATR (ATM-Rad3-related), checkpoint kinase 1 (CHK1), BRCA1, NBS1, and RAD51 by Western blotting and immunofluorescence. Significantly, DNMT1-deficient cells demonstrated profound defects in these responses, including complete lack of {gamma}-H2AX induction and blunted p53 and CHK1 activation, while DNMT3B-deficient cells generally showed mild defects. We identified a novel interaction between DNMT1 and checkpoint kinase CHK1 and showed that the defective damage response in DNMT1-deficient cells is at least in part due to altered CHK1 subcellular localization. This study therefore greatly enhances our understanding of the mechanisms underlying 5-azadC cytotoxicity and reveals novel functions for DNMT1 as a component of the cellular response to DNA damage, which may help optimize patient responses to this agent in the future.

* Corresponding author. Mailing address: Department of Biochemistry and Molecular Biology, University of Florida, College of Medicine, Box 100245, 1600 SW Archer Rd., Gainesville, FL 32610. Phone: (352) 392-1810. Fax: (352) 392-2953. E-mail: keithr{at}ufl.edu

{triangledown} Published ahead of print on 8 November 2007.

Molecular and Cellular Biology, January 2008, p. 752-771, Vol. 28, No. 2
0270-7306/08/$08.00+0     doi:10.1128/MCB.01799-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Li, Q., Bartlett, D. L., Gorry, M. C., O'Malley, M. E., Guo, Z. S. (2009). Three Epigenetic Drugs Up-Regulate Homeobox Gene Rhox5 in Cancer Cells through Overlapping and Distinct Molecular Mechanisms. Mol. Pharmacol. 76: 1072-1081 [Abstract] [Full Text]  
  • Figueroa, M. E., Skrabanek, L., Li, Y., Jiemjit, A., Fandy, T. E., Paietta, E., Fernandez, H., Tallman, M. S., Greally, J. M., Carraway, H., Licht, J. D., Gore, S. D., Melnick, A. (2009). MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114: 3448-3458 [Abstract] [Full Text]  
  • Nakano, T., Katafuchi, A., Matsubara, M., Terato, H., Tsuboi, T., Masuda, T., Tatsumoto, T., Pack, S. P., Makino, K., Croteau, D. L., Van Houten, B., Iijima, K., Tauchi, H., Ide, H. (2009). Homologous Recombination but Not Nucleotide Excision Repair Plays a Pivotal Role in Tolerance of DNA-Protein Cross-links in Mammalian Cells. J. Biol. Chem. 284: 27065-27076 [Abstract] [Full Text]  
  • Fandy, T. E., Herman, J. G., Kerns, P., Jiemjit, A., Sugar, E. A., Choi, S.-H., Yang, A. S., Aucott, T., Dauses, T., Odchimar-Reissig, R., Licht, J., McConnell, M. J., Nasrallah, C., Kim, M. K. H., Zhang, W., Sun, Y., Murgo, A., Espinoza-Delgado, I., Oteiza, K., Owoeye, I., Silverman, L. R., Gore, S. D., Carraway, H. E. (2009). Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114: 2764-2773 [Abstract] [Full Text]  
  • Woyach, J. A, Shah, M. H (2009). New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer 16: 715-731 [Abstract] [Full Text]  
  • Gopalakrishnan, S., Sullivan, B. A., Trazzi, S., Della Valle, G., Robertson, K. D. (2009). DNMT3B interacts with constitutive centromere protein CENP-C to modulate DNA methylation and the histone code at centromeric regions. Hum Mol Genet 18: 3178-3193 [Abstract] [Full Text]  
  • Ruzov, A., Shorning, B., Mortusewicz, O., Dunican, D. S., Leonhardt, H., Meehan, R. R. (2009). MBD4 and MLH1 are required for apoptotic induction in xDNMT1-depleted embryos. Development 136: 2277-2286 [Abstract] [Full Text]  
  • Hoglund, A., Nilsson, L. M., Forshell, L. P., Maclean, K. H., Nilsson, J. A. (2009). Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 113: 4281-4288 [Abstract] [Full Text]  
  • Xiong, J., Epstein, R. J. (2009). Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status. Molecular Cancer Therapeutics 8: 779-785 [Abstract] [Full Text]  
  • Link, P. A., Baer, M. R., James, S. R., Jones, D. A., Karpf, A. R. (2008). p53-Inducible Ribonucleotide Reductase (p53R2/RRM2B) Is a DNA Hypomethylation-Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous Leukemia. Cancer Res. 68: 9358-9366 [Abstract] [Full Text]  
  • Leng, S., Stidley, C. A., Bernauer, A. M., Picchi, M. A., Sheng, X., Frasco, M. A., Van Den Berg, D., Gilliland, F. D., Crowell, R. E., Belinsky, S. A. (2008). Haplotypes of DNMT1 and DNMT3B are associated with mutagen sensitivity induced by benzo[a]pyrene diol epoxide among smokers. Carcinogenesis 29: 1380-1385 [Abstract] [Full Text]  
  • Beltran, A. S., Sun, X., Lizardi, P. M., Blancafort, P. (2008). Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Molecular Cancer Therapeutics 7: 1080-1090 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»